Skip to main content
Article thumbnail
Location of Repository

The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists

By Michael A Shapiro, Yu Ling Chang, Sarah K Munson, Charles E Jacobson, Ramon L Rodriguez, Frank M Skidmore, Michael S Okun and Hubert H Fernandez

Abstract

Several studies have related pathological gambling in PD to dopamine agonist therapy. A mail-in survey was sent to PD patients seen at the University of Florida Movement Disorders Center to determine gambling frequency and behavior, and any lifestyle or environmental factors associated with compulsive gambling in PD. 462 surveys were sent and 127 completed surveys were returned, of which ten were from patients who met criteria for compulsive gambling. All ten were taking dopamine agonists coincident with the compulsive gambling. Compulsive gamblers were younger, and psychological distress measures revealed that compulsive gamblers exhibited higher levels of anxiety, anger, and confusion. Thus in this cohort, we have uncovered the several characteristics of the most likely PD compulsive gambler, namely: (young) age, “angry”, “anxious”, and using a (dopamine) agonist

Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2654528
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1996). A study of the dopamine D2 receptor gene in pathological gambling.
    2. (1997). Altered dopamine function in pathological gambling. Psychol Med,
    3. (1990). Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Prog Brain Res,
    4. (2004). By carrot or stick: Cognitive reinforcement learning in Parkinsonism.
    5. (2005). Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
    6. (2004). Disabling repetitive behaviors in Parkinson’s disease. Mov Disord,
    7. (2004). Dopamine transmission in the human striatum during monetary reward tasks.
    8. (2005). Gambling among older, primary-care patients: an important public health concern.
    9. (2005). Health and psychosocial correlates of disordered gambling in older adults.
    10. (2000). Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies.
    11. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
    12. (2005). Motor fl uctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord,
    13. (2004). Parkinson’s disease is associated with goal-setting defi cits during task switching.
    14. (2000). Pathologic gambling in Parkinson’s Disease: A behavioral manifestation of pharmacologic treatment? Mov Disord,
    15. (2003). Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease.
    16. (2000). Pathological gambling behaviour: Emergence secondary to treatment of Parkinson’s disease with dopaminergic agents. Depress Anxiety,
    17. (2005). Pathological gambling caused by drugs used to treat Parkinson’s disease.
    18. (2004). Pathological gambling in two patients on dopamine replacement therapy for Parkinson’s disease. Neurol Sci,
    19. (2004). Pathological gambling, gender, and risk-taking behaviors. Addict Behav,
    20. (2005). Pharmacotherapy of Parkinson’s disease in Germany.
    21. (2000). Probabilistic learning and reversal defi cits in patients with Parkinson’s disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication.
    22. (2000). The DRD2 gene in psychiatric and neurological disorders and its phenotypes.
    23. (2005). Therapeutic strategies for Parkinson’s disease [Article in French].
    24. (1992). What features improve the accuracy of clinical diagnosis in Parkinson’s disease.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.